A systematic review and meta-analysis of the seroconversion rates and adverse effects of COVID-19 mRNA vaccine and COVID-19 viral vector vaccine in kidney transplant recipient patients

References

• Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BK, Chan YH, et al. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. doi:10.1136/bmj-2021-068632.
   PubMedGoogle Scholar
• Han X, Xu P, Ye Q. Analysis of COVID-19 vaccines: types, thoughts, and application. J Clin Lab Anal. 2021;35(9):e23937. doi:10.1002/jcla.23937.
   PubMed Web of Science ®Google Scholar
• Park H, Park MS, Seok JH, You J, Kim J, Kim J, Park M-S. Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. J Microbiol. 2022;60(3):308–8. doi:10.1007/s12275-022-1598-x.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384(23):2187–201. doi:10.1056/NEJMoa2101544.
   PubMed Web of Science ®Google Scholar
• Glebova K, Reznik ON, Reznik AO, Mehta R, Galkin A, Baranova A, Skoblov M. siRNA technology in kidney transplantation: current status and future potential. BioDrugs. 2014;28(4):345–61. doi:10.1007/s40259-014-0087-0.
   PubMed Web of Science ®Google Scholar
• Zhu L, Xu X, Ma K, Yang J, Guan H, Chen S, Chen Z, Chen G. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020;20(7):1859–63. doi:10.1111/ajt.15869.
   PubMed Web of Science ®Google Scholar
• Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744. doi:10.3389/fimmu.2019.01744.
   PubMed Web of Science ®Google Scholar
• Zeng H. mTOR signaling in immune cells and its implications for cancer immunotherapy. Cancer Lett. 2017;408:182–9. doi:10.1016/j.canlet.2017.08.038.
   PubMed Web of Science ®Google Scholar
• Maeda T, Obata R, Rizk DD, Kuno T. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City. J Med Virol. 2021;93(1):463–71. doi:10.1002/jmv.26365.
   PubMed Web of Science ®Google Scholar
• Hage R, Steinack C, Gautschi F, Schuurmans M. Transplant drugs against SARS, MERS and COVID-19. Transplantology. 2020;1(2):71–84. doi:10.3390/transplantology1020007.
   Google Scholar
• Ahmadian E, Zununi Vahed S, Mammadova S, Abediazar S. Immunosuppressant management in renal transplant patients with COVID-19. Biomed Res Int. 2021;2021:9318725. doi:10.1155/2021/9318725.
   PubMed Web of Science ®Google Scholar
• Cucchiari D, Egri N, Bodro M, Herrera S, Del Risco-Zevallos J, Casals-Urquiza J, Cofan F, Moreno A, Rovira J, Banon-Maneus E, et al. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021;21(8):2727–39. doi:10.1111/ajt.16701.
   PubMed Web of Science ®Google Scholar
• Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M, El Ouafi Z, Ponsard S, Berrahal I, Achard J-M, et al. Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol. 2021;32(9):2153–8. doi:10.1681/ASN.2021040490.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Bruminhent J, Setthaudom C, Phornkittikorn P, Chaumdee P, Prasongtanakij S, Srisala S, Malathum K, Boongird S, Nongnuch A, Assanatham M, et al. An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: a randomized controlled trial (CVIM 4 study). Am J Transplant. 2022;22(11):2651–60.
   PubMed Web of Science ®Google Scholar
• Heinzel A, Schretzenmeier E, Regele F, Hu K, Raab L, Eder M, Aigner C, Jabbour R, Aschauer C, Stefanski A-L, et al. Three-month follow-up of heterologous vs. homologous third SARS-CoV-2 vaccination in kidney transplant recipients: secondary analysis of a randomized controlled trial. Front Med (Lausanne). 2022;9:936126. doi:10.3389/fmed.2022.936126.
   PubMed Web of Science ®Google Scholar
• Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, Jabbour R, Hofbauer TM, Merrelaar A, Eder M, Regele F, Doberer K, Spechtl P, et al. Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial. JAMA Intern Med. 2022;182(2):165–71. doi:10.1001/jamainternmed.2021.7372.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, Silva J, Mao T, Oh JE, Tokuyama M, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315–20. doi:10.1038/s41586-020-2700-3.
   PubMed Web of Science ®Google Scholar
• Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of pfizer/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663–9. doi:10.26355/eurrev_202102_24877.
   PubMed Web of Science ®Google Scholar
• Bartlett BL, Pellicane AJ, Tyring SK. Vaccine immunology. Dermatol Ther. 2009;22(2):104–9. doi:10.1111/j.1529-8019.2009.01223.x.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Impact of vaccines universally recommended for children—United States, 1990–1998. MMWR Morb Mortal Wkly Rep. 1999;48(12):243–8.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Ten Great public health achievements—United States, 1900–1999. MMWR Morb Mortal Wkly Rep. 1999;48(12):241–3.
   PubMedGoogle Scholar
• Gardner P, Eickhoff T, Poland GA, Gross P, Griffin M, LaForce FM, Schaffner W, Strikas R. Adult immunizations. Ann Intern Med. 1996;124:35–40. doi:10.7326/0003-4819-124-1_Part_1-199601010-00007.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994;38(8):1695–702. doi:10.1128/AAC.38.8.1695.
   PubMed Web of Science ®Google Scholar
• Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, Ellefsen K, Bart P-A, Venetz J-P, Calandra T, Cavassini M. Humoral response to the influenza a H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011;52(2):248–56. doi:10.1093/cid/ciq104.
   PubMed Web of Science ®Google Scholar
• Birdwell KA, Ikizler MR, Sannella EC, Wang L, Byrne DW, Ikizler TA, Wright PF. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis. 2009;54(1):112–21. doi:10.1053/j.ajkd.2008.09.023.
   PubMed Web of Science ®Google Scholar
• Thuluvath PJ, Robarts P, Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol. 2021;75(6):1434–9. doi:10.1016/j.jhep.2021.08.008.
   PubMed Web of Science ®Google Scholar
• Kolb T, Fischer S, Müller L, Lübke N, Hillebrandt J, Andrée M, Schmitz M, Schmidt C, Küçükköylü S, Koster L, et al. Impaired immune response to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients. Kidney360. 2021;2(9):1491–8. doi:10.34067/KID.0003512021.
   PubMedGoogle Scholar
• Piotrowska M, Zieliński M, Tylicki L, Biedunkiewicz B, Kubanek A, Ślizień Z, Polewska K, Tylicki P, Muchlado M, Sakowska J, et al. Local and systemic immunity are impaired in end-stage-renal-disease patients treated with hemodialysis, peritoneal dialysis and kidney transplant recipients immunized with BNT162b2 Pfizer-BioNTech SARS-CoV-2 vaccine. Front Immunol. 2022;13:832924. doi:10.3389/fimmu.2022.832924.
   PubMed Web of Science ®Google Scholar
• Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One. 2013;8(2):e56974. doi:10.1371/journal.pone.0056974.
   PubMed Web of Science ®Google Scholar
• Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, Halkerston R, Hill J, Jenkin D, Stockdale L, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;27(2):279–88. doi:10.1038/s41591-020-01179-4.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475–84. doi:10.1038/s41577-021-00578-z.
   PubMed Web of Science ®Google Scholar
• Correia AL, Leal R, Pimenta AC, Fernandes M, Guedes Marques M, Rodrigues L, Santos L, Romãozinho C, Sá H, Pratas J, et al. The type of SARS-CoV-2 vaccine influences serological response in kidney transplant recipients. Clin Transplant. 2022;36(4):e14585. doi:10.1111/ctr.14585.
   PubMed Web of Science ®Google Scholar
• Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales MT, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacs): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398(10295):121–30. doi:10.1016/S0140-6736(21)01420-3.
   PubMed Web of Science ®Google Scholar
• Kerneis M, Bihan K, Salem JE. COVID-19 vaccines and myocarditis. Arch Cardiovasc Dis. 2021;114(6–7):515–7. doi:10.1016/j.acvd.2021.06.001.
   PubMed Web of Science ®Google Scholar
• Welsh KJ, Baumblatt J, Chege W, Goud R, Nair N. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2021;39:3329–32. doi:10.1016/j.vaccine.2021.04.054.
   PubMed Web of Science ®Google Scholar
• Sato K, Mano T, Niimi Y, Toda T, Iwata A, Iwatsubo T. Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database. Int J Infect Dis. 2021;111:310–2. doi:10.1016/j.ijid.2021.08.071.
   PubMed Web of Science ®Google Scholar
• Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Cutaneous adverse reactions associated with SARS-CoV-2 vaccines. J Clin Med. 2021;10(22):10. doi:10.3390/jcm10225344.
   Web of Science ®Google Scholar
• Dziedzic A, Riad A, Attia S, Klugar M, Tanasiewicz M. Self-reported adverse events of COVID-19 vaccines in polish healthcare workers and medical students. Cross-sectional study and pooled analysis of CoVaST project results in central Europe. J Clin Med. 2021;10(22):10. doi:10.3390/jcm10225338.
   Web of Science ®Google Scholar
• Cabanillas B, Novak N. Allergy to COVID-19 vaccines: a current update. Allergol Int. 2021;70(3):313–8. doi:10.1016/j.alit.2021.04.003.
   PubMed Web of Science ®Google Scholar